Investors and Media

Investor Relations

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Cancer is one of the most difficult diseases to treat. It is constantly changing, requiring new and more sophisticated therapies.

Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response.

Oncolytic immunotherapy enhances the effectiveness of immune checkpoint blockade and is expected to become the second cornerstone of immuno-oncology (IO) approaches, moving beyond incremental improvements in cancer treatment to help more patients overcome their disease.

Press Releases
Aug 01, 2022
WOBURN, Mass. , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and
Jun 03, 2022
WOBURN, Mass. , June 03, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Jason Rhodes , partner at Atlas Venture, has resigned from the